2026-06-01T18:18:30Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/87972024-03-14T11:52:07Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

00925njm 22002777a 4500 dc Aldred, Jason author Anca-Herschkovitsch, Marieta author Antonini, Angelo author Bajenaru, Ovidiu author Bourgeois, Paul author Cubo Delgado, Esther author Davis, Thomas L. author Iansek, Robert author Kovács, Norbert author Kukreja, Pavnit author Onuk, Koray author Pontieri, Francesco E. author Robieson, Weining author Siddiqui, Mustafa S. author Simu, Mihaela author Standaert, David G. author Chaudhuri, K. Ray author 2020-09 Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. 1758-2024 http://hdl.handle.net/10259/8797 10.2217/nmt-2020-0021 1758-2032 5-2-1 Criteria for advanced PD Dyskinesia LCIG Levodopa Levodopa-carbidopa intestinal gel Off time Parkinson’s disease Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE